Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance

Clemens, Ralf; Sänger, Roland; Kruppenbacher, J. P.; Höbel, Wilfried; Stanbury, William J.; Bock, Hans L.; Jilg, Wolfgang

doi:10.1016/s0264-410x(96)00205-8

Cited by 87 publications

(55 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many nonresponders can achieve seroprotective levels with one to three additional doses of the licensed, alum-adjuvanted vaccine. 26 In a randomized, controlled trial, increasing the antigen dose from 20 μg to 40 μg does not improve the rate of seroprotection to an additional dose of vaccine 14 although, in a retrospective analysis, higher antigen content is associated with higher rates of seroprotection in nonresponders. 18 A high-antigen-content vaccine with a novel adjuvant (MPL plus alum; AS04) is also associated with higher seroprotective rates and geometric mean antibody levels in nonresponders.…”

Section: Demographics and Participant Dispositionmentioning

confidence: 98%

Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

Halperin

Ward

Dionne³

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Demographics and Participant Dispositionmentioning

confidence: 98%

Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

Halperin

Ward

Dionne³

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…A non-response was defined as mean antiHBs antibody titers below 10 IU/L, low responders were those with titers between 10-99 IU/L, and those with anti-HBs titers more than 100 IU/L [13][14][15][16][17][18][19][20][21][22][23][24][25][26] were responders. A high response was on with titers more than 1 000 IU/l.…”

Section: Hbv Vaccination and Sample Collectionmentioning

confidence: 99%

Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders

Das

Gupta²,

Kumar³

et al. 2003

WJG

View full text Add to dashboard Cite

AIM:The study was initiated to evaluate the reactogenicity and immunogenicity of a recombinant hepatitis B vaccine in age group >40 years and to study the response of a single booster dose in primary non-responders to the hepatitis B vaccination. METHODS:A total of 102 volunteers without markers of hepatitis B infection (negative for HBsAg, anti-HBc antibody, HBeAg and anti-HBs antibody) received 20 µg of recombinant HB vaccine intramuscularly at 0, 1, and 6 months. Anti HBs titers were evaluated by a quantitative Elisa kit at 90 and 210 days. A booster dose of 20 µg HB vaccine was given after 6 months of the 3 rd vaccine dose to the 15 nonresponders and anti-HBs titers were measured after 1 month. RESULTS:Seroprotection (anti-HBs GMT³ 10 IU/L) was achieved in 85.3 % (87/102) volunteers. The mean GMT titers of the vaccine responders was 136.1 IU/L. Of the seroprotected individuals, there were 32.4 % (33/102) hyporesponders (antiHBs titers <10-99 mlU/ml) and 52.9 % (54/102) were responders (anti-HBs titers >100 IU/L). All the non-responders (15/15) responded to a single dose of the booster dose of recombinant HB vaccine and their mean anti-HBs antibody titers were more than 100.5 mIU/ml after the booster dose. CONCLUSION:Recombinant hepatitis B vaccine offers good seroprotection in the age group >40 years and has a good safety profile. A single booster dose after 6 months in primary non-responders leads to good seroprotective anti-HBs antibody titers. However, larger population based studies are needed to evaluate the role of a booster dose in selected group of non-responders and whether such an approach will be cost effective.Das K, Gupta RK, Kumar V, Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.

show abstract

“…6,20 This could lead to underestimating the proportion of youth who have received the vaccination. Lower response to anti-HBs is often observed among persons with chronic diseases (e.g., diabetes and chronic liver diseases) and those who are immunosuppressed (e.g., infected with HIV or hemodialysis patients).…”

Section: Vaccine-induced Immunity To Hepatitis B Among Canadian Streementioning

confidence: 99%

Trends in Vaccine-induced Immunity to Hepatitis B among Canadian Street-involved Youth

et al. 2010

View full text Add to dashboard Cite

In Canada, universal and publicly funded hepatitis B immunization programs have been available since 1998 in all provinces and territories. This present study estimates the proportion of having vaccine-induced immunity to hepatitis B virus (HBV) infection and its associated determinants among street-involved youth aged at 15-24 years old in Canada using the data collected by the Enhanced Surveillance of Canadian Street Youth. Vaccine-induced immunity was identified by blood test results of anti-HBc negative and anti-HBs positive. Of the 4,035 participants included in this study, the overall proportion of those with vaccine-induced immunity to HBV was 51.7% during the study period compared to over 90% among the general adolescent population. The proportion of street-involved youth immunized with HBV vaccine increased from 34.7% in 1999 to 64.4% in 2005. Immunity was higher among females (aOR=1.43, 1.17-1.75) and among those with a reported history of sexually transmitted infection (aOR=1.30, 1.03-1.63). The proportion of youth with the immunity decreased as age increased (aOR=0.78, 0.76-0.81, per year increase). Despite an overall increase in the proportion of Canadian street-involved youth with vaccineinduced immunity to HBV, the proportion was still significantly lower than that observed in the general adolescent population. This highlights the need to improve the access to basic health care and the immunization programs to HBV for street-involved youth through creative outreach programs and other multi-faceted approaches.

show abstract

Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance

Cited by 87 publications

References 20 publications

Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders

Trends in Vaccine-induced Immunity to Hepatitis B among Canadian Street-involved Youth

Contact Info

Product

Resources

About